JP2014511885A5 - - Google Patents

Download PDF

Info

Publication number
JP2014511885A5
JP2014511885A5 JP2014505544A JP2014505544A JP2014511885A5 JP 2014511885 A5 JP2014511885 A5 JP 2014511885A5 JP 2014505544 A JP2014505544 A JP 2014505544A JP 2014505544 A JP2014505544 A JP 2014505544A JP 2014511885 A5 JP2014511885 A5 JP 2014511885A5
Authority
JP
Japan
Prior art keywords
pyrazolo
pyrimidin
phenyl
amine
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014505544A
Other languages
English (en)
Japanese (ja)
Other versions
JP6222776B2 (ja
JP2014511885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/001737 external-priority patent/WO2012143144A1/en
Publication of JP2014511885A publication Critical patent/JP2014511885A/ja
Publication of JP2014511885A5 publication Critical patent/JP2014511885A5/ja
Application granted granted Critical
Publication of JP6222776B2 publication Critical patent/JP6222776B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014505544A 2011-04-21 2012-04-23 キナ−ゼ・インヒビタ−として有用なピラゾロ[4,3−d]ピリミジン Active JP6222776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161517582P 2011-04-21 2011-04-21
US61/517,582 2011-04-21
PCT/EP2012/001737 WO2012143144A1 (en) 2011-04-21 2012-04-23 Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2014511885A JP2014511885A (ja) 2014-05-19
JP2014511885A5 true JP2014511885A5 (https=) 2016-09-29
JP6222776B2 JP6222776B2 (ja) 2017-11-01

Family

ID=46017783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505544A Active JP6222776B2 (ja) 2011-04-21 2012-04-23 キナ−ゼ・インヒビタ−として有用なピラゾロ[4,3−d]ピリミジン

Country Status (26)

Country Link
US (1) US9802937B2 (https=)
EP (1) EP2699579B1 (https=)
JP (1) JP6222776B2 (https=)
KR (1) KR101649611B1 (https=)
CN (1) CN103492389B (https=)
AP (1) AP2013007253A0 (https=)
AU (1) AU2012244550C1 (https=)
BR (1) BR112013026521A2 (https=)
CA (1) CA2831634C (https=)
CL (1) CL2013003051A1 (https=)
CO (1) CO6831982A2 (https=)
CR (1) CR20130536A (https=)
CU (1) CU20130143A7 (https=)
EA (1) EA029040B1 (https=)
EC (1) ECSP13012982A (https=)
GT (1) GT201300255A (https=)
IL (1) IL228968A (https=)
MA (1) MA35124B1 (https=)
MX (1) MX363696B (https=)
PE (1) PE20140928A1 (https=)
PH (1) PH12013502185A1 (https=)
SG (1) SG194549A1 (https=)
TN (1) TN2013000419A1 (https=)
TW (1) TWI606049B (https=)
WO (1) WO2012143144A1 (https=)
ZA (1) ZA201307839B (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691399B1 (en) * 2011-03-28 2016-07-13 F.Hoffmann-La Roche Ag Thiazolopyrimidine compounds
MX363696B (es) 2011-04-21 2019-03-28 Origenis Gmbh Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas.
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
AR090650A1 (es) 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
US20120323214A1 (en) * 2012-05-16 2012-12-20 Totada R Shantha Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
WO2014001973A1 (en) 2012-06-29 2014-01-03 Pfizer Inc. NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
WO2014060112A1 (en) * 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9440952B2 (en) 2013-03-04 2016-09-13 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
WO2015026683A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN105828823B (zh) 2013-10-18 2019-06-14 美国印第安纳大学研究和技术公司 乙型肝炎病毒组装效应物
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン
KR20160106622A (ko) 2014-01-29 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
ES2717757T3 (es) * 2014-01-29 2019-06-25 Glaxosmithkline Ip Dev Ltd Compuestos
EA201691831A1 (ru) 2014-04-25 2017-02-28 Пфайзер Инк. Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
AU2016219102B2 (en) * 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
AU2016249021A1 (en) 2015-04-17 2017-10-19 Assembly Biosciences, Inc. Hepatitis B viral assembly effectors
CA3028355A1 (en) * 2015-06-26 2016-12-29 Kadmon Corporation, Llc Glucose uptake inhibitors
US10729691B2 (en) 2015-06-26 2020-08-04 Kadmon Corporation, Llc Treatment of infectious diseases with glucose uptake inhibitors
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
US9762007B2 (en) 2016-02-10 2017-09-12 Dish Network L.L.C. Push on connector
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
UA125650C2 (uk) 2016-09-09 2022-05-11 Інсайт Корпорейшн Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку
CN109996546B (zh) 2016-09-30 2023-06-27 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法
CN106667990A (zh) * 2016-11-17 2017-05-17 郑州郑先医药科技有限公司 一种治疗风湿病的药物
CN106620315A (zh) * 2016-11-17 2017-05-10 郑州郑先医药科技有限公司 一种用于治疗风湿病的药物组合物
US20180153922A1 (en) 2016-12-06 2018-06-07 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
CN106580974A (zh) * 2016-12-06 2017-04-26 郑州郑先医药科技有限公司 一种治疗脊髓损伤的西药组合物及其应用
US12539297B2 (en) 2017-02-07 2026-02-03 Oncocross Co., Ltd. Composition for inhibiting cancer metastasis and treating cancer
US11364237B2 (en) 2017-02-07 2022-06-21 Oncocross Co., Ltd. Composition for inhibiting cancer metastasis and treating cancer
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018195397A2 (en) * 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CN108178760B (zh) * 2017-12-27 2020-02-18 安徽医科大学 一种嘧啶并吡唑杂环化合物、制备方法、用途
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
WO2019162964A1 (en) * 2018-02-23 2019-08-29 Indian Institute Of Science Anti-tubercular composition, and combinatorial implementations thereof
US10689386B2 (en) 2018-03-07 2020-06-23 Duquesne University Of The Holy Spirit Pyrazolo[4,3-d]pyrimidines as antitumor agents
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
CN109867800B (zh) * 2019-04-01 2021-04-09 江西理工大学 一种镉基金属-有机框架及其制备方法
KR102702945B1 (ko) 2019-05-21 2024-09-05 보로노이 주식회사 N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2020247756A1 (en) * 2019-06-05 2020-12-10 Forcyte Biotechnologies, Inc. Small molecules to relax uterine smooth muscle contractions
EP3993764A4 (en) 2019-07-05 2023-08-23 Icahn School of Medicine at Mount Sinai HAIR LOSS PREVENTION METHODS
MX2022001562A (es) 2019-08-06 2022-04-26 Incyte Corp Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
CN110876752B (zh) * 2019-11-18 2021-04-30 暨南大学 长链非编码rna nron功能基序在制备抑制骨吸收及防治骨质疏松药物中的应用
PT4065582T (pt) 2019-11-26 2025-05-22 Ikena Oncology Inc Derivados polimórficos do carbazol e utilizações dos mesmos
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
CA3202773A1 (en) * 2020-10-26 2022-05-05 Neuron23, Inc. Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2
WO2023032987A1 (ja) * 2021-08-31 2023-03-09 日本たばこ産業株式会社 6-アミノピラゾロピリミジン化合物及びその医薬用途
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
JP2025539787A (ja) * 2022-11-16 2025-12-09 ヴァーンウィ セラピューティクス,インコーポレイテッド Tyk2阻害剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469868A (en) * 1982-05-24 1984-09-04 Warner-Lambert Company Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
GB8306481D0 (en) * 1983-03-09 1983-04-13 Beecham Group Plc Compounds
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
DE10113710A1 (de) 2001-03-16 2002-09-26 Joerg Rademann Oxoammoniumsalze sowie deren Verwendung
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
WO2005118588A1 (ja) * 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited 縮合複素環化合物
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
EP1903045A1 (en) 2005-05-27 2008-03-26 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine derivative
JP2007055940A (ja) 2005-08-24 2007-03-08 Astellas Pharma Inc ピラゾロピリミジン誘導体
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
US20100298557A1 (en) * 2006-12-28 2010-11-25 Taisho Pharmaceutical Co., Ltd Pyrazolopyrimidine compound
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ,インコーポレーテッド 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法
EA021293B1 (ru) 2008-12-08 2015-05-29 Джилид Коннектикут, Инк. ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
MX363696B (es) 2011-04-21 2019-03-28 Origenis Gmbh Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas.
AR090650A1 (es) 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo

Similar Documents

Publication Publication Date Title
JP2014511885A5 (https=)
AU2011234398B2 (en) Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
US20240109901A1 (en) Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
JP2014511884A5 (https=)
JP5400626B2 (ja) 置換イミダゾおよびトリアゾロピリミジン類
US9586962B2 (en) Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
JP5208962B2 (ja) 二環式ピリミジノンおよびその使用
US8242116B2 (en) Fused thiazole derivatives as kinase inhibitors
JP6105578B2 (ja) 複素環式プロテインキナーゼ阻害剤
US20070135454A1 (en) Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1)
CN102388055B (zh) 咪唑并[2,1-b][1,3,4]噻二唑衍生物
WO2015038417A1 (en) Compounds for regulating fak and/or src pathways
CN102307875A (zh) 吡咯并嘧啶基axl激酶抑制剂
US10065960B2 (en) NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
Nan et al. Design, synthesis, and biological evaluation of thiazole/thiadiazole carboxamide scaffold-based derivatives as potential c-Met kinase inhibitors for cancer treatment
US20240025922A1 (en) TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS